Oral Solid Dosage CDMO Market Top Players, Segments & Regional Trends By 2034.
Straits Research released its highly anticipated report, “Global Oral Solid Dosage CDMO Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 45.98 billion in 2025 and is anticipated to grow till USD 81.17 billion by 2034, growing at a CAGR of 6.56% from 2026-2034.
Market Dynamics
The oral solid dosage CDMO market is driven by the sustained expansion of oral drug pipelines across chronic therapies, where tablets and capsules remain the preferred administration route due to dosing convenience and patient adherence. Pharmaceutical companies increasingly outsource formulation development, scale-up, and commercial manufacturing to external partners to manage portfolio breadth, accelerate timelines, and reduce fixed infrastructure burden. However, the market faces restraint from complexity associated with transferring formulations across development and manufacturing stages, particularly for modified release and high potency products, where process sensitivity and equipment variability affect reproducibility. Regulatory scrutiny across global supply chains further increases coordination challenges for sponsors and CDMOs. Despite these constraints, a strong opportunity exists in the rising demand for specialized CDMOs with expertise in controlled release technologies, containment manufacturing, and integrated packaging solutions. Growth in lifecycle management activities such as reformulations, line extensions, and regional product adaptations supports long-term outsourcing engagement, positioning oral solid dosage CDMOs as strategic partners rather than transactional manufacturers.
Market Highlights
-
Product: Based on Product, the tablets segment dominated the market with a revenue share of 33.45% in 2025.
Mechanism: Based on the Mechanism, controlled release dominated the market with a revenue share of 44.56% in 2025.
Drug Potency: Based on Drug Potency, low-potency drugs dominated the market with a revenue share of 34.67%.
Service: Based on Service, contract development dominated the market with a revenue share of 23.45%.
End Use: Based on End Use, medium & small companies dominated the market with 44.56%.
Regional Insights: North America held a dominant share of the global market, accounting for 37.54% in 2025.
Lonza Thermo Fisher Scientific Inc. Cambrex Corporation Catalent Inc. Siegrfried Holding AG Recipharm AB CordenPharma International Boehringer Ingelheim Piramal Pharma Solutions Aenova Group Almac Group Jubilant Pharmova Limited Delpharm AbbVie Contract Manufacturing Next Pharma AB Rubicon Research Pvt. Ltd. Quotient Sciences SPI Pharma DPT Laboratories Ltd. Alcami Corporation Others Recent Developments
February 2024: Novo Holdings announced the acquisition of Catalent Inc., a prominent CDMO in the healthcare industry. Through this acquisition, Novo Holdings gained market growth opportunities, and Catalent broadened its operational capabilities.
SegmentationBy Product (2026-2034) Tablets Compressed Tablets Orally Disintegrating Tablets (ODT) Chewable Tablets Bi-layer or Tri-layer Tablets Sublingual or Buccal Tablets Others Capsules Hard Gelatin Capsules Soft Gelatin Capsules Powders Granules Others By Mechanism (2026-2034) Immediate Release Delayed Release Controlled Release By Drug Potency (2026-2034) High Potent Drugs Moderate Potent Drugs Low Potent Drugs By Service (2026-2034) Contract Development Contract Manufacturing Packaging and Labelling Regulatory Affairs Logistics & Storage Others By End Use (2026-2034) Large Size Companies Medium & Small Size Companies Others Chat with us on WhatsApp
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment